Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitor
Background PD-1/PD-L1 engagement and overexpression of galectin-3 (Gal-3) are critical mechanisms of tumor-induced immune suppression that contribute to immunotherapy resistance. We hypothesized that Gal-3 blockade with belapectin (GR-MD-02) plus anti-PD-1 (pembrolizumab) would enhance tumor respons...
Main Authors: | William L Redmond, Yoshinobu Koguchi, Annah S Rolig, Noriko Iwamoto, Takashi Shimada, Elizabeth R Sturgill, Zhaoyu Sun, Venkatesh Rajamanickam, Brady Bernard, Peter G Traber, Eliezer Zomer, J Rex Horton, Harold Shlevin |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2021-04-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Online Access: | https://jitc.bmj.com/content/9/4/e002371.full |
Similar Items
-
Galectin-3 inhibition with belapectin combined with anti-OX40 therapy reprograms the tumor microenvironment to favor anti-tumor immunity
by: Elizabeth R. Sturgill, et al.
Published: (2021-01-01) -
Therapy of experimental NASH and fibrosis with galectin inhibitors.
by: Peter G Traber, et al.
Published: (2013-01-01) -
The role of Galectin-3 in modulating tumor growth and immunosuppression within the tumor microenvironment
by: Mohammad Farhad, et al.
Published: (2018-06-01) -
Regression of fibrosis and reversal of cirrhosis in rats by galectin inhibitors in thioacetamide-induced liver disease.
by: Peter G Traber, et al.
Published: (2013-01-01) -
A twist in the tail
by: Karen Guillemin, et al.
Published: (2014-03-01)